The CRO and medical genetics company will collaborate to accelerate trials centered on rare diseases, using real-world data and genetic testing technology.
The pharmaceutical company’s Lilly Institute for Genetic Medicine reportedly will focus on developing RNA-based therapeutics in a ‘state-of-the-art’ facility.
During OSP’s exclusive February 23 webinar Rare and Orphan Diseases, leading expertswill lend their unique experience and expertise to the important topic.
The US medical research agency plans to offer funding over five years through a newly launched consortium, expected to include 30 sites across the country.
The two companies are collaborating to research, develop and launch new small-molecule drug candidates aimed at treating obesity and related comorbidities.
In partnership with 23andMe, the group has released a wealth of new de-identified data from the largest-ever Parkinson’s cohort, to aid future research.
The online DNA network has delved into self-reported data of more than 563,000 US adults to help identify genetic risk of infection and severe outcomes.
Kazia therapeutics is collaborating with the Alliance for Clinical Trials in Oncology Foundation to launch a Phase II study to investigate its brain cancer therapies targeted at tumors’ genetic profile.
Circuit Clinical partners with the University at Buffalo’s genomics and biorepository program to add personalized medicine capabilities to its service offering lineup.
Centogene and Denali entered a strategic collaboration to identify and recruit patients with a gene mutation to be enrolled in a Parkinson’s disease study.
The joint drug discovery project announced yesterday will combine Centogene’s genetic testing service offerings with Evotec's iPSC platform and drug discovery capabilities.
WCG and InformedDNA have established a new center for genetics and precision medicine in clinical trials – the increasing complexity of which, while potentially daunting, also creates the opportunity for transformational value, say industry experts.
Spark Therapeutics has received US approval for Luxturna (voretigene neparvovec-rzyl), its one-time gene therapy treatment for an inherited form of vision loss.
Charles River Laboratories has announced an "end-to-end" service offering of CRISPR/Cas9 genome engineering technology, including custom in vivo and in vitro genome editing.
Sekisui XenoTech announced that it now offers genotyped hepatocytes for polymorphic enzyme drug metabolism studies as part of its cell- and tissue-based product catalog.
Plasticell has teamed up with encapsulation and screening tech firm Sphere Fluidics to develop genetic modification technology for cell therapy production.
The Broad Institute of MIT and Harvard is teaming up with Google Genomics to break down technical barriers hindering biomedical research by creating tools to analyze reams of new genomic data.
WuXi NextCODE and Fudan University have partnered to bring WuXi’s population human genomics database system and integrated research and clinical tools to the Fudan-led Collaborative Innovation Center of Genetics and Development (CICGD).
Gene-editing technology CRISPR-Cas9 must not be used to alter human DNA until the risks have been researched and the ethical issues considered, say scientists.
Chinese service provider WuXi PharmaTech has acquired NextCODE Health, a US and Icelandic genomic analysis and bioinformatics company, for $65m in cash.
Quintiles has signed a deal with Population Genetics Technologies (PGT) that, it says, will bring large-scale genomics analysis into the drug development mainstream.
Contract research organisation (CRO) Quintiles gained new ‘first-in-human’ (FIH) trial capacity yesterday with the opening of an ‘experimental medicine hub’ at Guy’s Hospital in London, UK.
Sigma-Aldrich is using a novel methodology to create rats with targeted gene deletion in as little as four months, which it believes could eliminate years of research and improve drug development.
Clinical Data is to sell Cogenics division, which provides services including sequencing and gene expression, to Beckman Coulter’s Agencourt Biosciences' business for $17m.
Researchers have used Affymetrix Genome-Wide Human SNP (single nucleotide polymorphism) arrays to discover genetic variations that increase the risk of schizophrenia.
Genomic services firm Expression Analysis has purchased the
first-ever commercially-available technology to allow the
sequencing of a single molecule of DNA, without amplification.
Integrated DNA Technologies (IDT) has launched LabLinker, a free
online system for sharing genome sequence data and even share
shipping costs of orders.
WaferGen has launched a new subsidiary in Kedah, Malaysia, with the
express purpose of overseeing research and development of its
real-time PCR system.
The UK's largest charity, the Wellcome Trust, has awarded £1.3m
(€1.9m) to fund the world's largest ever genome-wide association
study to identify the genetic origins of Alzheimer's disease.
The discoverer of embryonic stem cells (ES cells) and two other
scientists have won a Nobel Prize for their work to develop a
'magic wand' to modify the mouse genome.
Mobious Genomics has announced a prototype version of a new
immunoassay that identified a low concentration bacterial sample
within 40 seconds, vastly improving on the six - forty eight hours
it currently takes to identify the same...
